Want to see DE:M12 full AI Analyst Report?

M1 Kliniken AG (M12) Price & Analysis

13 Followers

M12 Stock Chart & Stats

€18.36

€0.30(1.71%)

At close: Jul 28 4:00 PM EDT

€18.36

€0.30(1.71%)

Day’s Range― - ―

52-Week Range€13.50 - €21.70

Previous CloseN/A

Volume52.00

Average Volume (3M)3.66K

Market Cap

€371.14M

Enterprise Value€336.14

Total Cash (Recent Filing)€60.50M

Total Debt (Recent Filing)€5.90M

Price to Earnings (P/E)18.7

Beta0.34

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.88%

Share Statistics

EPS (TTM)1.09

Shares Outstanding18,555,115

10 Day Avg. Volume5,778

30 Day Avg. Volume3,661

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)2.94

Price to Sales (P/S)0.97

P/FCF Ratio9.32

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.03

Revenue Forecast (FY)€137.00M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage and a larger equity base provide financial flexibility for clinic expansion, resilience during demand fluctuations, and capacity to fund operations without relying heavily on additional borrowing. This strengthens the company’s balance-sheet durability.

Strong Recent Cash GenerationStrong operating and free cash flow indicate that reported earnings are translating into cash, supporting reinvestment, debt avoidance, and shareholder returns. The improvement in 2025 gives the clinic and distribution businesses greater capacity to sustain growth internally.

Improved Earnings And GrowthMulti-year revenue expansion combined with substantially higher net income suggests improved scale and operating performance across the business. Higher profitability can strengthen reinvestment capacity and support the network’s ability to build earnings over the medium term.

Bears Say

Margin VolatilityUneven gross-margin performance makes it harder to establish how durable the stronger 2024 profitability level is. If margins fluctuate with treatment mix, product sales, or operating conditions, earnings growth may prove less predictable than revenue growth.

Volatile Cash ConversionThe sharp 2023 cash-flow trough shows that accounting profitability may not convert consistently into operating cash in every year. Such variability can complicate investment planning and make internally funded expansion less predictable during weaker periods.

Slowing Revenue GrowthThe continued slowdown in annual revenue growth indicates that the company’s expansion momentum has moderated. Sustaining medium-term earnings growth may therefore require stronger same-clinic demand, additional locations, or improved performance from Haemato & Derm.

M12 FAQ

What was M1 Kliniken AG’s price range in the past 12 months?

M1 Kliniken AG lowest stock price was €13.50 and its highest was €21.70 in the past 12 months.

What is M1 Kliniken AG’s market cap?

M1 Kliniken AG’s market cap is €371.14M.

When is M1 Kliniken AG’s upcoming earnings report date?

M1 Kliniken AG’s upcoming earnings report date is Nov 18, 2026 which is in 62 days.

How were M1 Kliniken AG’s earnings last quarter?

M1 Kliniken AG released its earnings results on Sep 09, 2026. The company reported €0.52 earnings per share for the quarter.

Is M1 Kliniken AG overvalued?

According to Wall Street analysts M1 Kliniken AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does M1 Kliniken AG pay dividends?

M1 Kliniken AG pays a Annually dividend of €1.2 which represents an annual dividend yield of 5.88%. See more information on M1 Kliniken AG dividends here

What is M1 Kliniken AG’s EPS estimate?

M1 Kliniken AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does M1 Kliniken AG have?

M1 Kliniken AG has 18,555,115 shares outstanding.

What happened to M1 Kliniken AG’s price movement after its last earnings report?

M1 Kliniken AG reported an EPS of €0.52 in its last earnings report. Following the earnings report the stock price went up 0.494%.

Which hedge fund is a major shareholder of M1 Kliniken AG?

Currently, no hedge funds are holding shares in DE:M12

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

M1 Kliniken AG Stock Smart Score

Outperform

Technicals

Fundamentals

Return on Equity

5.88%

Trailing 12-Months

Asset Growth

-12.73%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

M1 Kliniken AG

M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company's operations are segmented into two core divisions: Beauty and Trade. The Beauty segment is responsible for the creation and commercialization of pharmaceutical, medical, and medical technology products tailored for aesthetic medicine and cosmetic dermatology. Meanwhile, the Trade segment engages in the distribution of pharmaceuticals, biosimilars, and other medical products and devices, serving critical therapeutic areas such as oncology, HIV, rheumatology, neurology, cardiovascular conditions, and narcotics. Products are supplied to healthcare professionals, pharmacies, and wholesale distributors under the "M1 Select" brand. M1 Kliniken AG's operational footprint encompasses a network of outpatient specialist centers, a specialized surgical clinic center, and 46 distinct specialist locations branded as "M1 Med Beauty." Additionally, the company is involved in the acquisition, administration, and divestiture of real estate, predominantly within the healthcare industry.